Version July 2025
Skin and soft tissue infection (alternative agent):
Note: Reserve for patients with or at risk for methicillin-resistant S. aureus infection who cannot receive preferred agents (Ref).
Oral, IV: 200 mg once daily (Moran 2014; Prokocimer 2013). Total duration of therapy is ≥5 days; may extend up to 14 days depending on severity and clinical response (Ref).
Missed doses: Administer as soon as possible any time up to 8 hours prior to the next scheduled dose; if less than 8 hours remain before the next dose, wait until the next scheduled dose.
No dosage adjustment necessary.
No dosage adjustment necessary.
Refer to adult dosing.
(For additional information see "Tedizolid: Pediatric drug information")
Dosage guidance:
Safety: Dosages are presented in mg/kg/dose and flat mg doses depending on patient weight; use caution.
Skin and soft tissue infection:
Infants, Children, and Adolescents:
IV:
1 to <2 kg: IV: 3 mg/kg/dose every 12 hours for 6 days.
2 to <3 kg: IV: 6 mg every 12 hours for 6 days.
3 to <6 kg: IV: 12 mg every 12 hours for 6 days.
6 to <10 kg: IV: 20 mg every 12 hours for 6 days.
10 to <14 kg: IV: 30 mg every 12 hours for 6 days.
14 to <20 kg: IV: 40 mg every 12 hours for 6 days.
20 to <35 kg: IV: 60 mg every 12 hours for 6 days.
≥35 kg: IV: 200 mg once daily for 6 days (Ref).
Oral: Children and Adolescents weighing ≥35 kg: Oral: 200 mg once daily for 6 days (Ref).
Infants, Children, and Adolescents: Any degree of kidney impairment or patients receiving hemodialysis: Oral, IV: No dosage adjustment necessary; not removed by hemodialysis.
Infants, Children, and Adolescents: Oral, IV: No dosage adjustment necessary.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise specified.
1% to 10%:
Cardiovascular: Flushing (<2%), hypertension (<2%), palpitations (<2%), phlebitis (children, adolescents: 3%), tachycardia (<2%)
Dermatologic: Dermatitis (<2%), pruritus (<2%), urticaria (<2%)
Gastrointestinal: Clostridioides difficile colitis (<2%), diarrhea (4%), nausea (7%), oral candidiasis (<2%), vomiting (adolescents, adults: 1% to 3%)
Genitourinary: Vulvovaginal infection (fungal: <2%)
Hematologic & oncologic: Anemia (children, adolescents, adults: <2%), decreased platelet count (<112,000/mm3: children, adolescents, adults: 1% to 2%), decreased white blood cell count (<2%)
Hepatic: Increased gamma-glutamyl transferase (<2%), increased serum alanine aminotransferase (children, adolescents, adults: ≤3%), increased serum aspartate aminotransferase (children, adolescents, adults: ≤3%)
Hypersensitivity: Hypersensitivity reaction (<2%), infusion-related reaction (≤4%)
Local: Injection-site reaction (≤4%)
Nervous system: Dizziness (2%), facial nerve paralysis (<2%), headache (5%), hypoesthesia (<2%), insomnia (<2%), paresthesia (<2%), peripheral neuropathy (1%)
Ophthalmic: Asthenopia (<2%), blurred vision (<2%), visual impairment (<2%), vitreous opacity (<2%)
<1%:
Hematologic & oncologic: Decrease in absolute neutrophil count (<800/mm3)
Ophthalmic: Optic neuropathy
Postmarketing: Hematologic & oncologic: Thrombocytopenia
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
Disease-related concerns:
• Neutropenia: Not recommended for use in patients with neutrophil counts <1000 cells/mm3. Alternative therapies should be considered when treating patients with neutropenia and acute bacterial skin and skin structure infections (ABSSI).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Intravenous, as phosphate [preservative free]:
Sivextro: 200 mg (1 ea)
Tablet, Oral, as phosphate:
Sivextro: 200 mg
No
Solution (reconstituted) (Sivextro Intravenous)
200 mg (per each): $444.58
Tablets (Sivextro Oral)
200 mg (per each): $558.10
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Administer with or without food.
Intravenous: Administer as an IV infusion over 1 hour; do not administer as an IV push or bolus. Not for intra-arterial, IM, intrathecal, intraperitoneal, or subcutaneous administration. If the same IV line is to be used for sequential infusion of other drugs or solutions, the line should be flushed with NS before and after tedizolid infusion.
Oral: Administer with or without food.
Missed dose: Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose. All prescribed doses should be administered even if a dose is missed.
Parenteral: IV: Administer as an IV infusion over 1 hour; do not administer as an IV push or bolus. Not for intra-arterial, IM, intrathecal, intraperitoneal, or SUBQ administration. If the same IV line is to be used for sequential infusion of other drugs or solutions, the line should be flushed with NS before and after tedizolid infusion.
200 mg in 250 mL (concentration: 0.8 mg/mL) of NS only
Skin and soft tissue infections: Treatment of adults and pediatric patients ≥26 weeks GA and ≥1 kg with acute bacterial skin and soft tissue infections caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
Mycobacterial (nontuberculous, rapidly growing) infection
Inhibits BCRP;
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Alpelisib: BCRP/ABCG2 Inhibitors may increase serum concentration of Alpelisib. Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions. Risk D: Consider Therapy Modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may increase neuroexcitatory and/or seizure-potentiating effects of Amifampridine. Risk C: Monitor
Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor
ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor
ARIPiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Asenapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification
BCG (Intravesical): Antibiotics may decrease therapeutic effects of BCG (Intravesical). Risk X: Avoid
BCG Vaccine (Immunization): Antibiotics may decrease therapeutic effects of BCG Vaccine (Immunization). Risk C: Monitor
BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Tedizolid may increase serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor
Benperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Blonanserin: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Blonanserin. Specifically, the risk of seizures may be increased. Risk C: Monitor
Brexpiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Bromperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Bromperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
BuPROPion: May increase neuroexcitatory and/or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor
Cariprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ChlorproMAZINE. Specifically, the risk of seizures may be increased. Risk C: Monitor
Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid
Cladribine: BCRP/ABCG2 Inhibitors may increase serum concentration of Cladribine. Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration. Risk D: Consider Therapy Modification
Clothiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
CloZAPine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Risk C: Monitor
DroPERidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of DroPERidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Fecal Microbiota (Live) (Oral): May decrease therapeutic effects of Antibiotics. Risk X: Avoid
Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid
Flupentixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor
FluPHENAZine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Haloperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Iloperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor
Iohexol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor
Loxapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Lumateperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Lurasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Methotrimeprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Molindone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor
OLANZapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of OLANZapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Paliperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
PAZOPanib: BCRP/ABCG2 Inhibitors may increase serum concentration of PAZOPanib. Risk X: Avoid
Periciazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Perphenazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Pimozide: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pimozide. Specifically, the risk of seizures may be increased. Risk C: Monitor
Pipamperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pipamperone. Specifically, the risk of seizures may be increased. Risk X: Avoid
Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor
Prochlorperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Promazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
QUEtiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of QUEtiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
RisperiDONE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor
Seladelpar: BCRP/ABCG2 Inhibitors may increase serum concentration of Seladelpar. Risk C: Monitor
Sertindole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sertindole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor
Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification
Sulpiride: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sulpiride. Specifically, the risk of seizures may be increased. Risk C: Monitor
Sympathomimetics: Tedizolid may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor
Talazoparib: BCRP/ABCG2 Inhibitors may increase serum concentration of Talazoparib. Risk C: Monitor
Thioridazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thioridazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Thiothixene: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor
Topotecan: BCRP/ABCG2 Inhibitors may increase serum concentration of Topotecan. Risk X: Avoid
Trifluoperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification
Ubrogepant: BCRP/ABCG2 Inhibitors may increase serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor. Risk D: Consider Therapy Modification
Ziprasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Adverse events were observed in animal reproduction studies.
It is not known if tedizolid is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Baseline complete blood count (CBC) with differential
After conversion from the prodrug, tedizolid phosphate, tedizolid binds to the 50S bacterial ribosomal subunit. This prevents the formation of a functional 70S initiation complex that is essential for the bacterial translation process and subsequently inhibits protein synthesis. Tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci (Kisgen 2014).
Absorption: Oral: Well absorbed.
Distribution:
Children 2 to <6 years: Vd: Single dose: Geometric mean range: 20.4 to 20.5 L (Arrieta 2021).
Children 6 to <12 years: Vd: Single dose: Geometric mean range: 29.4 to 31.1 L (Arrieta 2021).
Children ≥12 years and Adolescents ≤17 years (mean weight: 55.3 kg): Vdss: 54.2 ± 10.2 L (Bradley 2016).
Adults: Vdss: 67 to 80 L.
Protein binding: 70% to 90%.
Metabolism: Tedizolid phosphate is converted by phosphatases to tedizolid (active, parent drug); no other significant circulating metabolites.
Bioavailability: Oral: ~91%.
Half-life elimination:
Children 2 to <6 years: IV: Geometric mean range: 5.51 to 5.76 hours (Arrieta 2021).
Children 6 to <12 years: IV: Geometric mean range: 4.93 to 5.18 hours (Arrieta 2021).
Children ≥12 years and Adolescents ≤17 years: IV, Oral: 6.64 to 8.26 hours (Bradley 2016).
Adults: ~12 hours.
Time to peak: Oral: ~3 hours; IV: 1 to 1.5 hours.
Excretion: Feces (82%) and urine (18%), both as inactive sulfate conjugates. Less than 3% excreted in feces or urine as parent drug.
Anti-infective considerations:
Parameters associated with efficacy:
S. aureus: fAUC24/minimum inhibitory concentration; goal: ~20 to 50 (bacteriostasis); ~35 to 105 (1-log kill) (Lepak 2012; Louie 2011).
Expected drug exposure in patients with normal renal function:
Cmax (peak):
Single dose, 200 mg:
Adolescents 12 to 17 years of age: Oral: 2.23 ± 0.55 mg/L; IV: 3.85 ± 1.51 mg/L (Bradley 2016).
Adults, BMI <30 kg/m2: Oral: 2.3 mg/L; IV: 2.9 mg/L (Flanagan 2017).
Adults, BMI ≥30 kg/m2: Oral: 1.9 mg/L; IV: 2.5 mg/L (Flanagan 2017).
Multiple dose (steady state):
Neonates (GA ≥26 weeks), Infants, Children, and Adolescents <18 years:
1 to <2 kg: IV: 3 mg/kg/dose every 12 hours: Geometric mean: 2.3 mg/L.
2 to <3 kg: IV: 6 mg every 12 hours: Geometric mean: 1.8 mg/L.
3 to <6 kg: IV: 12 mg every 12 hours: Geometric mean: 2.4 mg/L.
6 to <10 kg: IV: 20 mg every 12 hours: Geometric mean: 2.2 mg/L.
10 to <14 kg: IV: 30 mg every 12 hours: Geometric mean: 2.7 mg/L.
14 to <20 kg: IV: 40 mg every 12 hours: Geometric mean: 2.7 mg/L.
20 to <35 kg: IV: 60 mg every 12 hours: Geometric mean: 2.6 mg/L.
≥35 kg: 200 mg once daily: Geometric mean: IV: 3.8 mg/L; Oral: 2.5 mg/L.
Adults: 200 mg once daily: Oral: 2.2 ± 0.6 mg/L; IV: 3 ± 0.7 mg/L.
AUC:
Single dose, 200 mg: AUC0 to ∞:
Adolescents 12 to 17 years of age: Oral: 25.2 ± 9.2 mg•hour/L; IV: 27.8 ± 7.3 mg•hour/L (Bradley 2016).
Adults, BMI <30 kg/m2: Oral: 28.5 mg•hour/L; IV: 28.7 mg•hour/L (Flanagan 2017).
Adults, BMI ≥30 kg/m2: Oral: 25.4 mg•hour/L; IV: 25.4 mg•hour/L (Flanagan 2017).
Multiple dose (steady state): AUC24:
Neonates (GA ≥26 weeks), Infants, Children, and Adolescents <18 years:
1 to <2 kg: IV: 3 mg/kg/dose every 12 hours: Geometric mean: 33.1 mg•hour/L.
2 to <3 kg: IV: 6 mg every 12 hours: Geometric mean: 20.8 mg•hour/L.
3 to <6 kg: IV: 12 mg every 12 hours: Geometric mean: 26.4 mg•hour/L.
6 to <10 kg: IV: 20 mg every 12 hours: Geometric mean: 22.5 mg•hour/L.
10 to <14 kg: IV: 30 mg every 12 hours: Geometric mean: 27.6 mg•hour/L.
14 to <20 kg: IV: 40 mg every 12 hours: Geometric mean: 28.4 mg•hour/L.
20 to <35 kg: IV: 60 mg every 12 hours: Geometric mean: 31.4 mg•hour/L.
≥35 kg: 200 mg once daily: Geometric mean: IV: 30.6 mg•hour/L; Oral: 29.3 mg•hour/L.
Adults: 200 mg once daily: Oral: 25.6 ± 8.5 mg•hour/L; IV: 29.2 ± 6.2 mg•hour/L.
Postantibiotic effect: Staphylococcus spp. (including methicillin-resistant): 0.05 to 0.7 hours; Enterococcus spp. (including vancomycin-resistant): 0.1 to 1.3 hours (Locke 2014).
